These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 19249182)

  • 21. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia.
    Benko R; Matuz M; Doro P; Peto Z; Molnar A; Hajdu E; Nagy E; Gardi J; Soos G
    Int J Antimicrob Agents; 2007 Aug; 30(2):162-8. PubMed ID: 17570646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.
    Nandy P; Samtani MN; Lin R
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2354-9. PubMed ID: 20385854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.
    Ambrose PG; Bhavnani SM; Rubino CM; Louie A; Gumbo T; Forrest A; Drusano GL
    Clin Infect Dis; 2007 Jan; 44(1):79-86. PubMed ID: 17143821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic issues for antibiotics in the critically ill patient.
    Roberts JA; Lipman J
    Crit Care Med; 2009 Mar; 37(3):840-51; quiz 859. PubMed ID: 19237886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges.
    Nalda-Molina R; Dokoumetzidis A; Charkoftaki G; Dimaraki E; Margetis K; Archontaki H; Markantonis S; Boutos N; Sakas D; Vryonis E; Skoutelis A; Valsami G
    J Antimicrob Chemother; 2012 Jul; 67(7):1722-9. PubMed ID: 22457313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New developments in carbapenems.
    Kattan JN; Villegas MV; Quinn JP
    Clin Microbiol Infect; 2008 Dec; 14(12):1102-11. PubMed ID: 19076841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide.
    Dorr MB; Jabes D; Cavaleri M; Dowell J; Mosconi G; Malabarba A; White RJ; Henkel TJ
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii25-30. PubMed ID: 15750034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing drug exposure to minimize selection of antibiotic resistance.
    Olofsson SK; Cars O
    Clin Infect Dis; 2007 Sep; 45 Suppl 2():S129-36. PubMed ID: 17683017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients?
    Pea F; Viale P
    Clin Infect Dis; 2006 Jun; 42(12):1764-71. PubMed ID: 16705585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance.
    Udy AA; Roberts JA; De Waele JJ; Paterson DL; Lipman J
    Int J Antimicrob Agents; 2012 Jun; 39(6):455-7. PubMed ID: 22483562
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical pharmacology of carbapenems in neonates.
    Pacifici GM; Allegaert K
    J Chemother; 2014 Apr; 26(2):67-73. PubMed ID: 24090536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic/pharmacodynamic modeling and simulation to determine effective dosage regimens for doripenem.
    Katsube T; Yano Y; Wajima T; Yamano Y; Takano M
    J Pharm Sci; 2010 May; 99(5):2483-91. PubMed ID: 19904828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumonia.
    Housman ST; Kuti JL; Nicolau DP
    Clin Chest Med; 2011 Sep; 32(3):439-50. PubMed ID: 21867814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens.
    Scaglione F; Paraboni L
    Int J Antimicrob Agents; 2008 Oct; 32(4):294-301. PubMed ID: 18621508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of doripenem penetration into human prostate tissue and assessment of dosing regimens for prostatitis based on site-specific pharmacokinetic-pharmacodynamic evaluation.
    Nakamura K; Ikawa K; Yamada Y; Arakawa M; Zennami K; Nishikawa G; Ikeda K; Morikawa N; Honda N
    J Chemother; 2012 Feb; 24(1):32-7. PubMed ID: 22546722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
    Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
    J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock.
    Varghese JM; Roberts JA; Lipman J
    Crit Care Clin; 2011 Jan; 27(1):19-34. PubMed ID: 21144984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamics of antimicrobial drugs.
    Levison ME
    Infect Dis Clin North Am; 2004 Sep; 18(3):451-65, vii. PubMed ID: 15308272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill.
    Tsai D; Lipman J; Roberts JA
    Curr Opin Crit Care; 2015 Oct; 21(5):412-20. PubMed ID: 26348420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.